STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer

Wu,Jingjing; Lai,Maode; Shao,Changshun; Wang,Jian; Wei,Jian-Jun

doi:10.3892/or.2015.4120

STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer

Authors:
- Jingjing Wu
- Maode Lai
- Changshun Shao
- Jian Wang
- Jian-Jun Wei
View Affiliations

Affiliations: Department of Pathology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China, Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, Piscataway, NJ 08854, USA, Department of Surgical Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China, Department of Pathology, Northwestern University School of Medicine, Chicago, IL 60611, USA
Published online on: July 9, 2015 https://doi.org/10.3892/or.2015.4120
Pages: 1494-1502

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High-grade serous cancer (HGSC) is a lethal form of ovarian cancer due to invasion and early metastasis. Gain of epithelial-mesenchymal transition (EMT) contributes to the aggressiveness of HGSC. High-mobility gene group A2 (HMGA2), an architectural transcription factor, plays a major role in HGSC through the regulation of EMT gene expression. Based on the gene profiling analysis, we found that the potent EMT gene, stanniocalcin 2 (STC2), was highly correlated with HMGA2 expression. In the present study, we demonstrated that STC2 was directly regulated by HMGA2 at the transcriptional level. Overexpressing STC2 in vitro directly enhanced cell migration and invasion. To investigate the correlation of STC2 and HMGA2 expression and the potential biomarker for ovarian cancer, three independent large cohorts of ovarian cancer (cohort 1=278, cohort 2=150 and cohort 3=95 cases) were examined in the present study. The results showed that the expression of HMGA2 and STC2 was positively correlated. Furthermore, STC2 expression was significantly associated with tumor grade and histotype. HGSC had significantly higher levels of STC2 expression and was inversely correlated with patient survival. These findings suggested that STC2 is an important new biomarker that can be used for HGSC.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Coleman RL, Monk BJ, Sood AK and Herzog TJ: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kurman RJ and Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol. 34:433–443. 2010. View Article : Google Scholar : PubMed/NCBI
4	Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E and Peter ME: Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 6:2585–2590. 2007. View Article : Google Scholar : PubMed/NCBI
5	Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA and Hampton GM: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA. 98:1176–1181. 2001. View Article : Google Scholar : PubMed/NCBI
6	Wei JJ, Wu J, Luan C, Yeldandi A, Lee P, Keh P and Liu J: HMGA2: A potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol. 34:18–26. 2010. View Article : Google Scholar
7	Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, Narita M, Muller W, Liu J and Wei JJ: HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res. 71:349–359. 2011. View Article : Google Scholar : PubMed/NCBI
8	Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R and Tchernitsa O: HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer. 123:348–356. 2008. View Article : Google Scholar : PubMed/NCBI
9	Wu J and Wei JJ: HMGA2 and high-grade serous ovarian carcinoma. J Mol Med Berl. 91:1155–1165. 2013. View Article : Google Scholar : PubMed/NCBI
10	Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, D'Armiento J and Chada K: HMGA2 is a driver of tumor metastasis. Cancer Res. 73:4289–4299. 2013. View Article : Google Scholar : PubMed/NCBI
11	Zha L, Zhang J, Tang W, Zhang N, He M, Guo Y and Wang Z: HMGA2 elicits EMT by activating the Wnt/β-catenin pathway in gastric cancer. Dig Dis Sci. 58:724–733. 2013. View Article : Google Scholar
12	Serlachius M, Alitalo R, Olsen HS and Andersson LC: Expression of stanniocalcin-1 in megakaryocytes and platelets. Br J Haematol. 119:359–363. 2002. View Article : Google Scholar : PubMed/NCBI
13	Chang AC and Reddel RR: Identification of a second stanniocalcin cDNA in mouse and human: Stanniocalcin 2. Mol Cell Endocrinol. 141:95–99. 1998. View Article : Google Scholar : PubMed/NCBI
14	Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH and Liu J: Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst. 102:812–827. 2010. View Article : Google Scholar : PubMed/NCBI
15	Ieta K, Tanaka F, Yokobori T, Kita Y, Haraguchi N, Mimori K, Kato H, Asao T, Inoue H, Kuwano H, et al: Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int J Cancer. 125:926–931. 2009. View Article : Google Scholar : PubMed/NCBI
16	Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, Mankaruos M, Youssef Y, Khalil B, Khella H, et al: Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res. 72:5273–5284. 2012. View Article : Google Scholar : PubMed/NCBI
17	Yuan Y, Yang ZL, Zou Q, Li JH, Li DQ, Liang LF, Zeng GX and Chen SL: Comparative study of clinicopathological significance, BIRC7, and STC2 expression between squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Neoplasma. 60:698–705. 2013. View Article : Google Scholar : PubMed/NCBI
18	Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D, Sandaltzopoulos R, Liotta LA, Gimotty PA and Coukos G: Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol. 25:852–861. 2007. View Article : Google Scholar : PubMed/NCBI
19	Law AY and Wong CK: Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res. 316:466–476. 2010. View Article : Google Scholar
20	McMillen BD, Aponte MM, Liu Z, Helenowski IB, Scholtens DM, Buttin BM and Wei JJ: Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma. Mod Pathol. 25:1644–1653. 2012. View Article : Google Scholar : PubMed/NCBI
21	Cui T and Leng F: Specific recognition of AT-rich DNA sequences by the mammalian high mobility group protein AT-hook 2: A SELEX study. Biochemistry. 46:13059–13066. 2007. View Article : Google Scholar : PubMed/NCBI
22	Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE and Venter DJ: Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res. 62:1289–1295. 2002.PubMed/NCBI
23	Law AY and Wong CK: Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp Cell Res. 316:3425–3434. 2010. View Article : Google Scholar : PubMed/NCBI
24	Yokobori T, Mimori K, Ishii H, Iwatsuki M, Tanaka F, Kamohara Y, Ieta K, Kita Y, Doki Y, Kuwano H, et al: Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann Surg Oncol. 17:2601–2607. 2010. View Article : Google Scholar : PubMed/NCBI
25	Wang YY, Li L, Zhao ZS and Wang HJ: Clinical utility of measuring expression levels of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer. World J Surg Oncol. 11:812013. View Article : Google Scholar : PubMed/NCBI
26	Volland S, Kugler W, Schweigerer L, Wilting J and Becker J: Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma. Int J Cancer. 125:2049–2057. 2009. View Article : Google Scholar : PubMed/NCBI
27	Wang H, Wu K, Sun Y, Li Y, Wu M, Qiao Q, Wei Y, Han ZG and Cai B: STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro. BMB Rep. 45:629–634. 2012. View Article : Google Scholar : PubMed/NCBI
28	Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D'Andrea K, Attiyeh EF, Simon MC and Nathanson KL: Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res. 72:112–121. 2012. View Article : Google Scholar :